Please provide your email address to receive an email when new articles are posted on . 38% of patients with cutaneous lupus erythematosus displayed evidence of positive interferon (IFN)-alpha ...

In a study spanning almost three decades, the use of interferon alfa-2b led to durable remission for patients with low-grade lymphomatoid granulomatosis and increased overall survival compared with ...

Interferon therapies are well established as treatment options for some types of cancer, but they have not been used to treat cancers characterized by the overproduction of blood cells. The FDA has ...

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma Seventy-nine patients (40 with PV and 39 with ET) have ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Intron A is an injectible recombinant ...

A significant prolongation of relapse-free survival (P = .0023, one-sided) and prolongation of overall survival (P = .0237, one-sided) was observed with IFN alpha-2b therapy in this trial, which is ...

In a recent study posted to bioRxiv *, researchers performed an analysis of molecular variance (AMOVA) in 59 haplotypes of the interferon (IFN)-alpha (α) /beta (β) receptor (IFNAR) gene, departing ...

New research from The Wistar Institute's Montaner lab—led by Wistar Executive Vice President, director of the HIV Cure and Viral Disease Center, and Herbert Kean, M.D., Family Professor, Luis Montaner ...

Twenty-four patients with human papillomavirus (HPV)-associated cervical intraepithelial neoplasia (CIN); of whom 13 had CIN 1, 8 had CIN 2, and 3 had CIN 3; were treated with recombinant alpha 2b ...